(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) slid 9.34% to $0.49 at 11:24 EST on Thursday, following the last session’s upward trend. NASDAQ is dropping 0.63% to $12,080.25, following the last session’s upward trend. This seems, so far, a somewhat negative trend exchanging session today.
Xenetic Biosciences’s last close was $0.52, 54.16% below its 52-week high of $1.13.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-0.51.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.9%.
Yearly Top and Bottom Value
Xenetic Biosciences’s stock is valued at $0.49 at 11:24 EST, way below its 52-week high of $1.13 and way higher than its 52-week low of $0.24.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be oversold (<=20).
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 8.3% and 42.1%, respectively.
More news about Xenetic Biosciences (XBIO).
